CUMYL-PICA
Synthetic cannabinoid of the indole-3-carboxamide family, agonist at CB1 and CB2, named as a narcotic in France.
C₂₃H₂₈N₂O
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
Data sheet
Names
- IUPAC name
- 1-pentyl-N-(2-phenylpropan-2-yl)indole-3-carboxamide
- Other names
- SGT-56 · 1-pentyl-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide
Identifiers
- Formula
- C₂₃H₂₈N₂O
- Molar mass
- 348.50 g/mol
- CAS
- 1400742-32-6
- PubChem CID
- 86273678(new tab)
- InChIKey
- RCXFMWJQOYCIQU-UHFFFAOYSA-N
Class
- Family
- Synthetic cannabinoid (SCRA)
Updated on
Receptors and activity
- CB1Agonist70 out of 100
Ki 59,2 nM (IC 95 % 45,9 à 76,3) sur hCB1 (Gamage et coll., 2018) ; CE50 de 11,98 nM en [35S]-GTPγS (même étude)
- CB2Agonist62 out of 100
Ki 136,3 nM (IC 95 % 103,8 à 178,9) sur hCB2 (Gamage et coll., 2018)
Subjective signature
- Calm
- 12 out of 100
- Relaxation of body and mind; reduced mental noise without marked drowsiness.
- Clarity
- 5 out of 100
- Sustained attention and clear thinking; functional lucidity, not euphoria.
- High
- 15 out of 100
- Euphoria and sensory intensity; altered perception of time and space.
- Appetite
- 18 out of 100
- Stimulation of hunger and of taste appreciation (the “munchies” effect).
- Sleep
- 12 out of 100
- Sedative effect: aids sleep onset and the continuity of deep sleep.
Pharmacology
CUMYL-PICA is an agonist at the CB1 and CB2 cannabinoid receptors, of the cumyl indole-3-carboxamide family. It binds with a higher affinity to CB1 (Ki of 59.2 nM) than to CB2 (Ki of 136.3 nM), and it activates CB1 at nanomolar concentrations (Gamage et al., 2018). In rats, it causes hypothermia and bradycardia (Longworth et al., 2017; Kevin et al., 2017). The sources consulted report no controlled clinical study and no controlled pharmacokinetic study in humans; they are preclinical or analytical.
Key sources.
- Longworth et coll., pharmacologie des carboxamides cumyle dont CUMYL-PICA, ACS Chemical Neuroscience, 2017 (new tab)PMID 28792725
- Gamage et coll., pharmacologie moléculaire et comportementale de CUMYL-PICA et d'autres cannabinoïdes de synthèse, Journal of Pharmacology and Experimental Therapeutics, 2018 (new tab)PMID 29549157
- Kevin et coll., pharmacocinétique et métabolisme de CUMYL-PICA et 5F-CUMYL-PICA, Forensic Toxicology, 2017 (new tab)PMID 28824730
- Kevin et coll., dégradants thermiques et cyanure issus de cannabinoïdes de synthèse de type carboxamide, Forensic Toxicology, 2019 (new tab)PMID 30705707
- ANSM, liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (annexe IV, dérivés du 3-carboxamide indole) (new tab)
- INCB, Green List 2026 (Convention de 1971) (new tab)
- PubChem, CUMYL-PICA, CID 86273678 (new tab)
History
- Source
- An entirely synthetic molecule, absent from cannabis. It is one of the synthetic cannabinoids found in products used recreationally; it was first detected in European products in 2014 (Kevin et al., 2017).
Origin (pharmaceutical research → illicit market)
No known biosynthetic pathway: a synthetic molecule, obtained exclusively by chemical synthesis within the cumyl indole carboxamide family.
Legal framework
- European Union
No harmonised European Union control measure is documented in the sources cited for this record. The compound does not appear in the INCB Green List 2026, which reproduces the schedules of the 1971 Convention.
- France
In France, CUMYL-PICA is named explicitly in the consolidated list of substances classified as narcotics published by ANSM (update of 16 February 2026), in annex IV, in the block on 3-carboxamide indole derivatives, under the heading « notably ». That generic definition also covers the molecule: an alkyl substituent (pentyl) on the indole nitrogen and a cumyl substituent on the amide nitrogen. All the conditions of that definition are met. It is therefore subject to French narcotics regulation.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
References
- Longworth et coll., pharmacologie des carboxamides cumyle dont CUMYL-PICA, ACS Chemical Neuroscience, 2017 (new tab)PMID 28792725
- Gamage et coll., pharmacologie moléculaire et comportementale de CUMYL-PICA et d'autres cannabinoïdes de synthèse, Journal of Pharmacology and Experimental Therapeutics, 2018 (new tab)PMID 29549157
- Kevin et coll., pharmacocinétique et métabolisme de CUMYL-PICA et 5F-CUMYL-PICA, Forensic Toxicology, 2017 (new tab)PMID 28824730
- Kevin et coll., dégradants thermiques et cyanure issus de cannabinoïdes de synthèse de type carboxamide, Forensic Toxicology, 2019 (new tab)PMID 30705707
- ANSM, liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (annexe IV, dérivés du 3-carboxamide indole) (new tab)
- INCB, Green List 2026 (Convention de 1971) (new tab)
- PubChem, CUMYL-PICA, CID 86273678 (new tab)
Structured data
- SMILES
- CCCCCN1C=C(C2=CC=CC=C21)C(=O)NC(C)(C)C3=CC=CC=C3
- InChIKey
- RCXFMWJQOYCIQU-UHFFFAOYSA-N
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.